Introduction
============

Obsessive--compulsive disorder (OCD) is a chronic debilitating disorder characterized by recurring unwelcome and intrusive thoughts, beliefs, impulses, images or urges (obsession) that typically cause anxiety, accompanied by repetitive mental or behavioral acts (compulsion) that individuals iterate to relieve their tension. OCD sufferers often realize that their obsessions and compulsions are irrational and excessive; nevertheless, they are not able to stop them.[@b1-ndt-14-1199],[@b2-ndt-14-1199] Despite recent changes to the *Diagnostic and Statistical Manual of Mental Disorders*-5 (DSM-V), which OCD removed from the anxiety section of the DSM and gave a chapter of its own, called Obsessive--Compulsive and Related Disorders, the core clinical features of OCD remain the same.[@b3-ndt-14-1199],[@b4-ndt-14-1199] Individuals with OCD may demonstrate a diversity of obsessions and compulsions. The Yale--Brown Obsessive Compulsive Scale (Y-BOCS), most widely used by OCD researchers and clinicians, is designed to categorize the type of symptoms and assess the severity of OCD.[@b5-ndt-14-1199]

OCD prevalence is estimated to be between 1.5% and 3% of the people worldwide, independent of ethnicity and cultural group studied.[@b6-ndt-14-1199] It is expected to become one of the top 10 leading causes of disability worldwide within the next 20 years.[@b7-ndt-14-1199] The study conducted by Koran to evaluate the quality of life in OCD patients has shown moderate or severe interference with socializing, family relationships, self-esteem and the ability to study and work.[@b8-ndt-14-1199] These functional impairments have burdened a significant expense on the society. It was indicated that the disability associated with OCD was about 47%, and the costs were estimated to be 10.6 billion dollars per annum in the US.[@b9-ndt-14-1199] Furthermore, studies[@b10-ndt-14-1199]--[@b12-ndt-14-1199] manifest that suicidal tendencies in OCD patients have been underestimated, and the rate of suicidality (suicidal thoughts, attempts and completed suicide) is reported to be from 20% to 46% among OCD sufferers.[@b13-ndt-14-1199] Considering its severity, high prevalence and apparent social cost, OCD has to be studied more extensively; there is a pressing need for further research to gain an improved recognition of its etiology and treatment.

Many etiological studies on OCD confirm that OCD is familial and heritable.[@b14-ndt-14-1199]--[@b18-ndt-14-1199] Family aggregation studies, the result from twin studies, functional neuroimaging, pharmacologic and molecular genetic studies have demonstrated convincing data for the genetic basis of OCD.[@b19-ndt-14-1199],[@b20-ndt-14-1199] Increasing progress in recent molecular biology techniques has led to an impressive interest to identify which genes are entailed in OCD etiology. Although a considerable segment of the genetic contribution to OCD remains unknown, genome-wide association studies and candidate gene studies provide convincing evidence for the importance of specific genes that may be involved in the expression of OCD.[@b21-ndt-14-1199] Moreover, several evidence are suggesting the impact of genetic factors on the response to drug treatment. Identification of biologic factors, which may be related to treatment response, could be extremely beneficial to gain appropriate clinical outcome.[@b22-ndt-14-1199] Based on the efficacy of selective serotonin reuptake inhibitors (SSRIs) in treating OCD,[@b23-ndt-14-1199] many genes with a role in the serotonergic system have been examined in genetic and pharmacogenetic studies.[@b19-ndt-14-1199],[@b24-ndt-14-1199]

A large family of serotonin (5-hydroxytryptamine \[5-HT\]) receptors has been recognized, including *5HT2A*, *HTR1B* and *5-HT2C*, and their associations with obsessive--compulsive symptoms and OCD treatment response have been studied extensively.[@b19-ndt-14-1199],[@b24-ndt-14-1199]--[@b26-ndt-14-1199] Serotonin receptor 2a is a critical receptor in the serotonergic pathway, which was found to be associated with many different behavioral disorders such as OCD,[@b27-ndt-14-1199] eating disorders,[@b28-ndt-14-1199] schizophrenia,[@b29-ndt-14-1199] alcoholism,[@b30-ndt-14-1199] depression[@b31-ndt-14-1199] and suicidal behavior.[@b32-ndt-14-1199] The gene for the *5-HT2A* receptor, *HTR2A*, is located on chromosome 13q14--q21.[@b33-ndt-14-1199] It spans 20 kb and includes three exons containing \>200 single-nucleotide polymorphisms (SNPs) along the gene.[@b32-ndt-14-1199] Two of the most remarkable SNPs of the *HTR2A* which were extensively studied in the OCD are rs6311 (1438G/A) and rs6313 (102C/T).[@b19-ndt-14-1199],[@b27-ndt-14-1199],[@b33-ndt-14-1199]--[@b38-ndt-14-1199] However, studies testing the hypothesis that allelic variations of the *HTR2A* could be associated with the drug response in OCD are limited.[@b39-ndt-14-1199] Although the functional significance of these polymorphisms is not entirely understood, there are pieces of evidence that rs6311 modulates transcription factor binding and promoter methylation, affecting gene transcription.[@b40-ndt-14-1199]

The current study aimed to investigate the presence of the association between the *HTR2A* polymorphism rs6311 and rs6313 and OCD and its clinical characteristics, as well as their role in OCD SSRI treatment responsiveness in Iranian population.

Subjects and methods
====================

Subjects
--------

In this study, the subjects consisted of 293 patients with OCD recruited from Imam Hossain Hospital (Tehran, Iran) and 245 healthy controls. The diagnosis of OCD was established by a psychiatrist based on DSM-IV-TR criteria for OCD. Obsessive and compulsive types and severities were evaluated by an expert psychologist through the structured interview using Y-BOCS checklist and severity scale. Participants were aged between 18 and 65 years. Also, patients with total Y-BOCS severity \<9, having OCD symptoms for \<1 year, reporting a history of psychotic disorders, mental retardation, severe neurologic pathology and other DSM-IV-TR Axis l disorders except for depression and anxiety, as well as those being under the SSRI or antidepressant pharmacotherapy were excluded. All patients and controls were matched for sex and age. The demographic characteristics of the patients are summarized in [Table 1](#t1-ndt-14-1199){ref-type="table"}. All participants gave written informed consent before they were included in the study. The study was approved by the Research Ethics Committee of Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran (IR.SBMU.PHNS. REC.1396.69).

Clinical data
-------------

Sociodemographic data were gathered by an interview based on a questionnaire including name and address, age at assessment, sex, marital status, ethnicity, educational level, occupation, age of onset (if symptoms started before 18 years of age, the patients were classified as early onset; otherwise, they were endorsed late onset[@b41-ndt-14-1199]), illness duration, history of substance use and the familial history of any psychiatric disorders, specifically OCD. In order to clarify the symptom and estimate the severity, the Persian version of Y-BOCS validated by Rajezi Esfahani et al[@b42-ndt-14-1199] was applied. The Global Assessment of Functioning was evaluated by the psychiatrist according to DSM-V Global Assessment of Functioning scale.

Study protocol
--------------

In this study, pharmacotherapy was defined as 12 weeks of treatment with fluvoxamine (100--300 mg). No concomitant therapy was allowed during the entire treatment period, either pharmacologic or nonpharmacologic. Of 352 patients who had participated in the current study, 293 patients were eligible for examination of genetic association analyses and about 131 patients completed their pharmacotherapy and were included in the pharmacogenetic study ([Figure 1](#f1-ndt-14-1199){ref-type="fig"}).

According to the reduction in patients' Y-BOCS score at the beginning of the treatment compared to the score after 12 weeks of treatment with fluvoxamine, patients were divided into two groups: group A (responders) was composed of patients who exhibited \>25% reduction in Y-BOCS scores after treatment with fluvoxamine and group B (non-responders) comprised patients who exhibited \<25% reduction in Y-BOCS scores.[@b43-ndt-14-1199],[@b44-ndt-14-1199] We also included another group (refractory patients) consisting of patients who experienced various SSRI trials during their illness period, but did not respond to them adequately.[@b45-ndt-14-1199]

Genotyping
----------

Venous blood (6 mL) of OCD patients and healthy controls was drawn, and DNA extraction was done by salting out method from peripheral blood cells according to the method which has been previously described.[@b46-ndt-14-1199] After DNA extraction, polymerase chain reaction (PCR) amplification was performed using Taq DNA polymerase 2x Master Mix (Ampliqon, Odense, Denmark; [www.ampliqon.com](http://www.ampliqon.com)) with specific primers for rs6311 (forward: 5′-AACCAACTTATTTCCTACCA-3′ and reverse: 5′-AAGCTGCAAGGTAGCAACAG-3′) and rs6313 (forward: 5′-AGCTCAACTACGAACTCCCT-3′ and 5′-GTAAGGAGAGACACGACGGT-3′). All the PCR reactions were done on a Bio-Rad T100 Thermal Cycler under the following program: 95°C for 7 min, 30 cycles of three repeating steps (denaturation at 95°C for 45 s, annealing at 58°C for 30 s and extension at 72°C for 30 s) and one final extension cycle at 72°C for 5 min. The PCR products were digested with MspI restriction enzyme (Cat No \#ER0541) for both SNPs and were subsequently loaded on 3% agarose gel to distinguish between different variants. Genotypes were confirmed by Sanger sequencing.

Statistical analysis
--------------------

Allelic and genotypic frequencies were subjected to SPSS (version 19.0; IBM Corporation, Armonk, NY, USA) to evaluate differences between the patient and control groups as well as the patients' stratified groups considering treatment responsiveness, sex and familial history of psychiatric disorders in different genetic models using chi-square statistics. The Hardy--Weinberg (H--W) equilibrium and haplotype analysis were also performed by means of chi-square test. After Bonferroni correction, statistical significance was assumed at the *P*-value \<0.008.

Results
=======

SNP association analyses with OCD
---------------------------------

The genotype distribution was tested by chi statistics and found to be in H--W equilibrium both in control subjects and patients (*P*=0.49 for rs6311 and *P*=0.46 for rs6313 in patients and *P*=0.49 for rs6311 and *P*=0.89 for rs6313 in controls).

[Table 2](#t2-ndt-14-1199){ref-type="table"} shows the results of association analyses of rs6311 and rs6313 with OCD based on different genetic models (co-dominance, dominant and recessive) considering sex. Results showed that none of the studied SNPs were associated with OCD in Iranian patients.

SNP association analyses with familial form of OCD
--------------------------------------------------

Results of genotypic association analyses with the family history of psychiatric disorders considering sex in different genetic models are summarized in [Table 3](#t3-ndt-14-1199){ref-type="table"}. When comparing the genotype distributions among patients according to the presence of family history of psychiatric disorders, association analysis of rs6311 showed no association with familial form of OCD. However, association analysis detected association of rs6313 with the presence of psychiatric disorder history under the recessive genetic model in female patients ([Table 3](#t3-ndt-14-1199){ref-type="table"}).

Haplotype association analysis
------------------------------

To examine the association of *HTR2a* haplotypes with OCD, haplotype analysis of the investigated polymorphisms was conducted. Haplotypes were defined as H1 (GC), H2 (GT), H3 (AC) and H4 (AT). The results showed significant differences between the haplotype frequencies of OCD patients and controls ([Table 4](#t4-ndt-14-1199){ref-type="table"}). OCD patients had less GC haplotype and more AC haplotype compared to controls.

Pharmacogenetic analysis
------------------------

Results of single locus association studies with fluvoxamine treatment response in OCD patients considering sex are summarized in [Table 5](#t5-ndt-14-1199){ref-type="table"}. Comparing the genotypic distribution in different treatment response groups (responders, non-responders and refractory patients) showed no significant differences for both the SNPs studied ([Table 5](#t5-ndt-14-1199){ref-type="table"}). However, two *HTR2A* haplotypes were associated with fluvoxamine treatment response in OCD ([Table 6](#t6-ndt-14-1199){ref-type="table"}). The responder group had more AC and less AT haplotypes compared to the non-responder group.

Discussion
==========

In this study, we hypothesized that *HTR2A* polymorphisms, rs6311 and rs6313, are associated with OCD and fluvoxamine treatment response in OCD patients. Results showed that each single locus was not associated with OCD, but their haplotypes were associated with OCD and its treatment response. Moreover, rs6313 was associated with the familial form of OCD in females.

To our knowledge, this is the first study addressing the genetic association of rs6311 and rs6313 with OCD in Iranian population and evaluating their associations with OCD treatment response. However, their associations with OCD were studied in other populations.

A meta-analysis by Taylor showed that the A allele of rs6311 or the linked T allele of rs6313 was significantly associated with OCD.[@b38-ndt-14-1199] This result was confirmed in the author's subsequent comprehensive meta-analysis in 2016 with a larger dataset.[@b47-ndt-14-1199] Although many studies have reported this association,[@b19-ndt-14-1199],[@b34-ndt-14-1199] there are inconsistent reports which have not focused on the association of *HTR2A* variants with OCD.[@b27-ndt-14-1199],[@b35-ndt-14-1199],[@b36-ndt-14-1199] The findings of Nicolini et al showed the lack of significant association between rs6313 and OCD.[@b36-ndt-14-1199] In a cross-sectional study, Meira-Lima et al examined the allelic and genotypic frequencies of the rs6313 variants in 79 OCD patients and 202 control subjects and observed no significant difference between the patients and controls.[@b27-ndt-14-1199] Our evaluations in the Iranian population also showed no association of rs6311 or rs6313 with OCD at the single locus. However, the patterns of their haplotypes were significantly different between OCD cases and control subjects.

There are limited studies evaluating the genetic association in the stratified patients' groups specifically considering sex or familial form of OCD. Enoch et al[@b48-ndt-14-1199] indicated that the rs6311 A allele was more abundant in females with OCD compared to control females. Results from a study conducted by Denys et al accounted that GG genotype of rs6311 was more frequent in patients with a family history of psychiatric disorders.[@b34-ndt-14-1199] We could not detect the association of rs6311 with a positive family history of OCD, but we found the association of rs6313 with the familial form of OCD in females. We previously detected the association of the functional serotonin transporter haplotype with the familial form of OCD in Iranian patients.[@b46-ndt-14-1199] Evidence for different genetic susceptibilities of the familial form of OCD compared to the non-familial form suggests different pathogenesis, which needs further investigation for a detailed elucidation.

The results of our pharmacogenetic study showed an association of *HTR2A* haplotypes with fluvoxamine treatment response in the OCD patients. Pharmacogenetic evaluations of *HTR2A* polymorphisms with SSRI treatment response are limited with inconsistent results. Zhang et al studied 113 OCD nuclear families which underwent SRI pharmacotherapy for 8 weeks, and they assessed the association of six genes including *HTR2A*, *5-HTT*, *DRD2*, *DRD4*, *COMT* and *MAOA*. Results showed no association between the six genes and different drug response groups, except for *HTR2A* rs6311.[@b49-ndt-14-1199] However, in another study examining 58 OCD patients, no association between rs6311 and rs6313 with treatment response was reported.[@b50-ndt-14-1199] Miguita et al also could not detect an influence of the rs6313 and 516C/T polymorphisms on treatment response in their sample of 41 OCD patients.[@b51-ndt-14-1199] Nonetheless, sample sizes in these studies are small, and using different SRIs is a confounding factor which may lead to inconsistencies in the results. Further studies in larger and more homogeneous clinical samples would help to have more explicit evidence related to the effects of these two SNPs on OCD treatment response.

This is the first study evaluating the role of *HTR2A* in OCD susceptibility and treatment response. The other strength of this study was prescribing a single drug, fluvoxamine, which avoided having confounding factors related to the different SSRI treatments. However, similar to any other research, we faced some limitations in this study. The most important limitation of this study is the sample size, so further replication studies with larger sample sizes are needed to confirm these preliminary findings. The other limitation is that we have not considered the environmental factors which may affect (positively or negatively) the treatment response.

Conclusion
==========

We have found that the *HTR2A* haplotype is associated with OCD in Iranian population and with fluvoxamine treatment response in OCD patients. Association of rs6313 with the familial form of OCD in females suggests conducting further studies on the genetic background of the familial and non-familial forms of OCD, which may shed light on its pathogenesis and more specific treatment strategies.
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###### 

Sociodemographic characteristics of OCD patients (N=293)

                                                  n          \%
  ----------------------------------------------- ---------- --------
  **Sex**                                                    
  Female                                          204        69.6
  Male                                            89         30.3
  **Marital status**                                         
  Single                                          82         27.9
  Married                                         211        72.0
  **Level of education**                                     
  School dropout                                  87         29.6
  Diploma                                         133        45.3
  Undergraduate                                   59         20.1
  Graduate                                        12         4.0
  Missing                                         2          0.6
  **Occupation**                                             
  Unemployed                                      175        59.7
  Employed                                        117        39.9
  Missing                                         1          0.3
  **Age of onset**                                           
  Early                                           82         27.9
  Late                                            210        71.6
  Missing                                         1          0.3
  **Familial history of psychiatric disorders**              
  Positive history                                233        79.5
  Negative history                                60         20.4
                                                             
                                                  **Mean**   **SD**
                                                             
  **Age (years)**                                            
  Age at assessment                               35.03      10.34
  Age of symptoms onset                           24.73      10.77
  **Y-BOCS current severity**                                
  Obsession                                       10.89      4.65
  Compulsion                                      9.40       5.66
  Total score                                     20         8.63

**Abbreviations:** OCD, obsessive--compulsive disorder; Y-BOCS, Yale--Brown Obses sive Compulsive scale.

###### 

Genotype distribution of the *HTR2A* polymorphisms in OCD patients and controls under different genetic models considering sex

  rs6311             Controls       Patients       *P*-value       OR       Lower--upper               
  ------------------ -------------- -------------- --------------- -------- ------------------ ------- --------------
  **Co-dominance**                                                                                     
  Female                                                                                               
   GG                27             23.4           61              30.3     0.310                      
   GA                64             55.6           95              47.3                                
   AA                24             22             45              23.4                                
  Male                                                                                                 
   GG                24             19.5           26              30.0     0.065                      
   GA                68             55.2           34              39.6                                
   AA                31             25.2           26              30.3                                
  Total                                                                                                
   GG                51             21.4           87              30.3     0.031                      
   GA                132            55.4           129             44.9                                
   AA                55             23.3           71              24.7                                
  **Dominance**                                                                                        
  Female                                                                                               
   GG+GA             91             79.1           156             77.6     0.753              1.094   0.626--1.912
   AA                24             20.8           45              22.3                                
  Male                                                                                                 
   GG+GA             92             74.7           60              69.7     0.422              1.028   0.696--2.377
   AA                31             25.2           26              30.23                               
  Total                                                                                                
   GG+GA             183            76.8           216             75.2     0.662              1.094   0.731--1.637
   AA                55             23.1           71              24.7                                
  **Recessive**                                                                                        
  Female                                                                                               
   GG                27             23.4           63              31.3     0.126              0.672   0.398--1.135
   GA+AA             88             76.5           138             68.6                                
  Male                                                                                                 
   GG                24             19.5           26              30.2     0.074              0.559   0.295--1.062
   GA+AA             99             80.4           60              69.7                                
  Total                                                                                                
   GG                51             21.4           89              31.0     0.013              0.607   0.408--0.903
   GA+AA             187            78.5           198             68.9                                
                                                                                                       
  **rs6313**         **Controls**   **Patients**   ***P*-value**   **OR**   **Lower--upper**           
  **n**              **%**          **n**          **%**                                               
                                                                                                       
  **Co-dominance**                                                                                     
  Female                                                                                               
   CC                29             25             63              31.0     0.465                      
   CT                61             52.5           94              46.3                                
   TT                26             22.4           46              22.6                                
  Male                                                                                                 
   CC                34             27.4           27              30.3     0.204                      
   CT                64             51.6           36              40.4                                
   TT                26             20.9           26              29.2                                
  Total                                                                                                
   CC                63             26.2           90              30.8     0.180                      
   CT                125            52.0           130             44.5                                
   TT                52             21.6           72              24.6                                
  **Dominance**                                                                                        
  Female                                                                                               
   CC+CT             90             77.3           157             77.3     0.992              1.003   0.581--1.733
   TT                26             22.6           46              22.6                                
  Male                                                                                                 
   CC+CT             98             79.2           63              70.7     0.157              1.571   0.838--2.947
   TT                26             20.8           26              29.2                                
  Total                                                                                                
   CC+CT             188            78.3           220             75.3     0.417              1.183   0.788--1.776
   TT                52             21.6           72              24.6                                
  **Recessive**                                                                                        
  Female                                                                                               
   CC                29             25.2           63              31.0     0.272              0.749   0.448--1.255
   CT+TT             87             74.7           140             68.9                                
  Male                                                                                                 
   CC                34             27.2           27              30.3     0.616              0.858   0.471--1.563
   CT+TT             90             72.8           62              69.6                                
  Total                                                                                                
   CC                63             26.2           90              30.8     0.246              0.799   0.546--1.168
   CT+TT             177            73.7           202             69.6                                

**Note:** Statistical significance considered as *P*-value \<0.008.

**Abbreviations:** OCD, obsessive--compulsive disorder; OR, odds ratio.

###### 

Genotype distribution of the *HTR2A* polymorphisms in familial form of OCD under different genetic models considering sex

  rs6311             Family history   *P*-value   OR    Lower--upper                   
  ------------------ ---------------- ----------- ----- -------------- ------- ------- --------------
  **Co-dominance**                                                                     
  Female                                                                               
   GG                23               46          39    26             0.040           
   GA                17               34          76    50.6                           
   AA                10               20          35    23.3                           
  Male                                                                                 
   GG                1                12.5        24    31.1           0.375           
   GA                3                37.5        31    40.2                           
   AA                4                50          22    28.5                           
  Total                                                                                
   GG                24               40.3        63    27.7           0.144           
   GA                20               35.0        107   47.1                           
   AA                14               24.5        57    25.1                           
  **Dominance**                                                                        
  Female                                                                               
   GG+CT             40               80          115   76.6           0.391   1.217   0.553--2.681
   AA                10               20          35    23.3                           
  Male                                                                                 
   GG+CT             4                50          55    76.6           0.195   0.400   0.092--1.742
   AA                4                50          22    71.4                           
  Total                                                                                
   GG+CT             44               75.8        170   74.8           0.514   1.054   0.538--2.064
   AA                14               24.1        57    25.1                           
  **Recessive**                                                                        
  Female                                                                               
   GG                22               44          39    71.4           0.014   2.236   1.148--4.357
   GA+AA             28               56          111   28.5                           
  Male                                                                                 
   GG                1                12.5        24    31.1           0.254   0.315   0.037--2.708
   GA+AA             7                87.5        53    68.8                           
  Total                                                                                
   GG                23               39.6        63    27.7           0.056   1.711   0.938--3.120
   GA+AA             35               60.3        164   72.2                           

**Note:**

*P*-value \<0.008.

**Abbreviations:** OCD, obsessive--compulsive disorder; OR, odds ratio.

###### 

Haplotype association analysis of *HTR2A* polymorphisms rs6311 and rs6313 with OCD

  Haplotype   rs6311   rs6313   Controls   Patients   *P*-value          
  ----------- -------- -------- ---------- ---------- ----------- ------ ---------------------------------------------------
  H1          G        C        467        40.9       295         31.2   0.047[\*](#tfn6-ndt-14-1199){ref-type="table-fn"}
  H2          G        T        135        11.8       167         17.6   0.117
  H3          A        C        141        12.3       197         20.8   0.029[\*](#tfn6-ndt-14-1199){ref-type="table-fn"}
  H4          A        T        397        34.8       285         30.1   0.336

**Note:**

*P*-value \<0.05.

**Abbreviation:** OCD, obsessive--compulsive disorder.

###### 

Genetic association analyses of the *HTR2A* polymorphisms with OCD treatment response under different genetic models considering sex

  rs6311             Responders       Non-responders       Refractory       *P*-value                      
  ------------------ ---------------- -------------------- ---------------- --------------- ------- ------ -------
  **Co-dominance**                                                                                         
  Female                                                                                                   
   GG                11               21.5                 5                25              3       20     0.281
   GA                29               56.8                 6                30              8       53.3   
   AA                11               21.5                 9                45              4       26.6   
  Male                                                                                                     
   GG                7                25                   2                22.2            1       12.5   0.856
   GA                11               39.8                 5                55.5            4       50     
   AA                10               35.7                 2                22.2            3       37.5   
  Total                                                                                                    
   GG                18               22.78                7                24.1            4       17.3   0.730
   GA                40               50.6                 11               37.9            12      52.1   
   AA                21               26.5                 11               37.9            7       30.4   
  **Dominance**                                                                                            
  Female                                                                                                   
   GG+GA             40               50.6                 11               55              11      73.3   0.140
   AA                11               13.9                 9                45              4       26.6   
  Male                                                                                                     
   GG+GA             18               64.2                 7                77.7            5       62.5   0.728
   AA                10               35.7                 2                22.2            3       37.5   
  Total                                                                                                    
   GG+GA             58               73.4                 18               62.0            16      69.5   0.519
   AA                21               26.5                 11               37.9            7       30.4   
  **Recessive**                                                                                            
  Female                                                                                                   
   GG                11               21.5                 5                55              3       20     0.930
   GA+AA             40               78.4                 15               45              12      80     
  Male                                                                                                     
   GG                7                25                   2                77.7            1       12.5   0.755
   GA+AA             21               75                   7                22.2            7       87.5   
  Total                                                                                                    
   GG                18               22.7                 7                24.1            4       17.3   0.824
   GA+AA             61               77.2                 22               75.8            19      82.6   
                                                                                                           
  **rs6313**         **Responders**   **Non-responders**   **Refractory**   ***P*-value**                  
  **n**              **%**            **n**                **%**            **n**           **%**          
                                                                                                           
  **Co-dominance**                                                                                         
  Female                                                                                                   
   CC                13               25                   6                30              3       20     0.111
   CT                29               55.7                 5                25              9       60     
   TT                10               19.2                 9                45              3       20     
  Male                                                                                                     
   CC                7                25                   2                22.2            1       12.5   0.904
   CT                12               42.8                 5                55.5            4       50     
   TT                10               32.1                 2                22.2            3       37.5   
  Total                                                                                                    
   CC                20               25                   8                27.5            4       17.3   0.436
   CT                41               51.2                 10               34.4            13      56.5   
   TT                19               23.7                 11               37.9            6       26.0   
  **Dominance**                                                                                            
  Female                                                                                                   
   CC+CT             42               80.7                 11               55              12      80     0.069
   TT                10               19.2                 9                45              3       20     
  Male                                                                                                     
   CC+CT             19               67.8                 7                77.7            5       62.5   0.780
   TT                9                32.1                 2                22.2            3       37.5   
  Total                                                                                                    
   CC+CT             61               76.2                 18               62.0            17      73.9   0.337
   TT                19               23.7                 11               37.9            6       26.0   
  **Recessive**                                                                                            
  Female                                                                                                   
   CC                13               25                   6                30              3       20     0.795
   CT+TT             39               75                   14               70              12      80     
  Male                                                                                                     
   CC                7                25                   2                22.2            1       12.5   0.755
   CT+TT             21               75                   7                77.7            7       87.5   
  Total                                                                                                    
   CC                20               25                   8                27.5            4       17.3   0.674
   CT+TT             60               75                   21               72.4            19      82.6   

**Note:** Statistical significance considered as *P*-value \<0.008.

**Abbreviation:** OCD, obsessive--compulsive disorder.

###### 

Haplotype association analysis of *HTR2A* polymorphisms rs6311 and rs6313 with OCD treatment response

  Haplotype   rs6311   rs6313   Responders   Non-responders   Refractory   *P*-value               
  ----------- -------- -------- ------------ ---------------- ------------ ----------- ---- ------ -----------------------------------------------------
  H1          G        C        112          35.6             39           37.1        25   27.1   0.072
  H2          G        T        38           12.1             11           10.4        15   16.3   0.185
  H3          A        C        46           14.6             0            0           17   18.4   0.0001[\*](#tfn10-ndt-14-1199){ref-type="table-fn"}
  H4          A        T        118          37.5             55           52.3        35   38.0   0.004[\*](#tfn10-ndt-14-1199){ref-type="table-fn"}

**Note:**

*P*-value \<0.05.

**Abbreviation:** OCD, obsessive--compulsive disorder.
